MedTrace Logo

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

NCT03931720 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-04-30

No results posted yet for this study

Summary

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the diagnosis and treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK/T cell immunotherapy for malignant tumors.

Conditions

  • Malignant Tumor

Interventions

BIOLOGICAL

BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)

The subject will be observed for any side effects during this time and all the adverse events will be recorded.

Sponsors & Collaborators

  • Asclepius Technology Company Group (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2021-05-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931720 on ClinicalTrials.gov